AbbVie: Enuresis trials

The registry lists 13 Enuresis studies with AbbVie as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 2 1Phase 3 6Phase 4 2No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary IncontinenceCompletedNCT03320850Phase 2Results posted
• Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary IncontinenceCompletedNCT03052764Phase 4Results posted
• OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)TerminatedNCT02097121Phase 3Results posted
• Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in BelgiumCompletedNCT02072928Results posted
• A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor OveractivityCompletedNCT01852058Phase 3Results posted
• Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric PatientsCompletedNCT01852045Phase 3Results posted
• A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary IncontinenceCompletedNCT01767519Phase 3Results posted
• Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)CompletedNCT01600716Phase 3Results posted
• Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary IncontinenceCompletedNCT00915525Phase 3Results posted
• A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean PatientsCompletedNCT02601287Phase 4
• A Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in IndiaCompletedNCT02590250
• An Observational Study of BOTOX® for the Management of Urinary Incontinence in Patients With Idiopathic Overactive BladderCompletedNCT02161159
• Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in KoreaCompletedNCT02010788